Biotechnology and its Applications — NEET notes

Bt Crops

Bt crops carry a gene from Bacillus thuringiensis that produces a crystal protein toxic to specific insect pests. The protoxin becomes active only in the alkaline gut of insects, making it harmless to humans. Bt cotton revolutionized Indian agriculture.

Bt Toxin Mechanism

Bacillus thuringiensis produces crystal (Cry) proteins during sporulation. These are inactive protoxins that get activated in the alkaline gut of susceptible insects, creating pores in the midgut lining and killing the insect.

Bacillus thuringiensis (Bt) is a soil bacterium that produces crystal proteins (Cry proteins) during sporulation. These crystals contain inactive protoxins — they're harmless in this form. The magic happens inside the insect.

How Bt Toxin Kills Insects — Step by Step

1. Insect larvae eat Bt crop tissue containing inactive Cry protoxin
2. In the alkaline gut (pH >9.5) of the insect, the protoxin is solubilized
3. Gut proteases cleave the protoxin into active toxin (smaller, toxic fragment)
4. Active toxin binds to specific receptors on midgut epithelial cells
5. Toxin creates pores in the cell membrane of the gut lining
6. Pores cause cell swelling and lysis — gut lining breaks down
7. Insect stops feeding, becomes septicemic, and dies within 2-3 days

• Bt toxin exists as inactive crystalline protoxin (called parasporal crystal) inside the bacterium
• Activation requires alkaline pH — found only in insect midgut, NOT in mammalian stomachs
• Active toxin is highly specific — it binds only to receptors on specific insect species
• Toxin creates pores in midgut epithelial cells, causing cell lysis and death
• The gene encoding the toxin is called cry gene (from 'crystal')

Cry Genes & Specificity

There are many types of cry genes, each producing a toxin specific to a particular group of insects. The naming convention tells you which pest group the toxin targets.

Not all Bt toxins are the same. There are many cry genes (cry stands for crystal), and each produces a protein toxic to a specific insect order. The gene name tells you the target: cryI genes target Lepidopterans (butterflies/moths), cryII target Lepidopterans and Dipterans, and cryIII target Coleopterans (beetles).

• cryIAc and cryIIAb — target Lepidoptera (cotton bollworms like *Heliothis*)
• cryIAb — targets corn borer (Lepidoptera, used in Bt corn)
• cryIIIAb and cryIIIBb — target Coleoptera (beetles like Colorado potato beetle)
• cryIVA and cryIVB — target Diptera (mosquitoes, flies)
• The Roman numeral tells you the insect order it targets — learn I, II, III, IV

Bt Cotton

Bt cotton carries cryIAc and cryIIAb genes that produce toxins against cotton bollworm (Heliothis/Helicoverpa). It was the first GM crop approved for commercial cultivation in India (2002).

Bt cotton is genetically modified cotton that carries the cryIAc and cryIIAb genes from *Bacillus thuringiensis*. These genes make the cotton plant produce Bt toxin in its tissues, which kills the cotton bollworm (*Helicoverpa armigera*) — the most devastating pest of cotton in India.

• Cry genes used: cryIAc and cryIIAb (both target Lepidoptera)
• Target pest: Cotton bollworm (*Helicoverpa armigera*)
• Approved in India: 2002 (first GM crop commercially released in India)
• Developed by: Mahyco-Monsanto (now Bayer)
• Reduced pesticide use by 60-70% and increased yield significantly

Other Bt crops mentioned in NCERT: Bt corn (cryIAb gene, targets corn borer) and Bt brinjal (cryIAc gene, targets fruit and shoot borer — approved in Bangladesh but not in India due to controversy).

Pest-Resistant Plants

Genetically engineering pest resistance into plants reduces dependence on chemical pesticides, lowers farmer costs, and reduces environmental pollution.

The traditional approach to pest control involves chemical pesticides — expensive, environmentally harmful, and often killing beneficial insects too. The genetic engineering approach inserts pest-resistance genes directly into the plant genome, making the plant defend itself. It's like giving a soldier a built-in bulletproof vest instead of an external shield.

• Bt crops reduce chemical pesticide use by 50-70%
• The toxin is specific to target insects — beneficial insects, birds, mammals are unaffected
• Bt toxin is a protein — it degrades during cooking and digestion
• Other strategies: protease inhibitors, lectins — also used to create pest-resistant plants
• NCERT mentions nematode-resistant tobacco using RNAi (different chapter concept)

RNA Interference (RNAi)

RNAi is a cellular mechanism where double-stranded RNA (dsRNA) triggers the silencing (degradation) of complementary mRNA, effectively shutting down the expression of a specific gene. This was used to create nematode-resistant tobacco plants.

RNAi Mechanism

When double-stranded RNA (dsRNA) complementary to a specific mRNA enters a cell, it triggers a defense pathway that chops up the target mRNA, preventing protein production.

RNA interference (RNAi) is a natural gene-silencing mechanism discovered by Andrew Fire and Craig Mello (Nobel Prize 2006). The cell uses it as a defense against viruses and transposons. In biotechnology, we exploit it to silence specific genes on purpose.

How RNAi Works — Step by Step

1. A double-stranded RNA (dsRNA) molecule complementary to the target mRNA is introduced into the cell
2. An enzyme called Dicer chops the dsRNA into small fragments called siRNA (small interfering RNA, ~21-23 nucleotides)
3. siRNA binds to a protein complex called RISC (RNA-Induced Silencing Complex)
4. RISC uses the siRNA as a guide to find and bind to the complementary mRNA in the cytoplasm
5. RISC cleaves (cuts) the target mRNA, destroying it
6. Without mRNA, the target gene's protein is NOT produced — gene is effectively silenced

• RNAi uses dsRNA to trigger gene silencing — NOT antisense RNA alone
• Dicer enzyme chops dsRNA into siRNA (small interfering RNA)
• RISC complex uses siRNA as a guide to find and degrade complementary mRNA
• The gene is still present in DNA — RNAi works at the post-transcriptional level
• RNAi is sequence-specific — only the target mRNA is destroyed

Nematode-Resistant Tobacco

Using RNAi, scientists created tobacco plants resistant to the root-knot nematode Meloidogyne incognita by silencing a nematode gene essential for its survival inside the plant.

Meloidogyne incognita (root-knot nematode) is a devastating parasite of tobacco roots. It infects roots and causes gall formation (swollen knots), reducing water and nutrient uptake. Scientists used RNAi to make tobacco plants immune to this nematode.

How RNAi-Based Nematode Resistance Was Achieved

1. Scientists identified a specific gene in *Meloidogyne incognita* essential for its survival
2. They created complementary sense and antisense RNA sequences of this nematode gene
3. Both sense and antisense RNA were introduced into the host tobacco plant using *Agrobacterium*-mediated transformation
4. Inside the plant cells, sense and antisense RNA hybridized to form dsRNA
5. When the nematode ingested plant cells, the dsRNA triggered RNAi inside the nematode
6. The nematode's essential gene was silenced — it could not survive in the plant
7. Result: Nematode-resistant tobacco plant with no chemical pesticides needed

• Parasite: Meloidogyne incognita (root-knot nematode)
• Host plant: Tobacco (*Nicotiana tabacum*)
• Strategy: Produce dsRNA in the plant that silences a nematode survival gene
• Both sense and antisense RNA produced in plant arrow form dsRNA
• Transformation done via *Agrobacterium tumefaciens*
• This is a host-delivered RNAi approach

RNAi vs Antisense Technology

Both RNAi and antisense technology silence gene expression, but they work through different mechanisms. Understanding the distinction helps avoid confusion in NEET.

Antisense RNA is a single-stranded RNA complementary to mRNA. It binds to mRNA directly, preventing ribosome attachment and translation. RNAi uses double-stranded RNA that triggers an enzymatic degradation pathway (Dicer → siRNA → RISC → mRNA cleavage). Both silence genes, but RNAi is more potent and catalytic.

• RNAi is catalytic — each siRNA-RISC complex can destroy multiple mRNA copies
• Antisense is stoichiometric — one antisense molecule blocks one mRNA
• Both work at the post-transcriptional level (mRNA is the target)
• In the nematode resistance example, both sense AND antisense RNA are made to form dsRNA for RNAi
• NCERT focuses on RNAi, not antisense technology — but understanding the difference helps

Transgenic Animals

Transgenic animals carry foreign genes inserted into their genome. They are used for studying disease, testing drugs, producing biological products (like human proteins in milk), verifying vaccine safety, and understanding gene regulation.

What Are Transgenic Animals

A transgenic animal has had its DNA deliberately modified by inserting a gene from another organism. The foreign gene (transgene) is expressed in the animal, giving it a new trait.

A transgenic animal is one whose genome has been altered by the insertion of a foreign gene (transgene) using genetic engineering. The transgene integrates into the animal's DNA and is inherited by offspring. Over 95% of transgenic animals created so far are mice — they're small, breed fast, and their genetics are well understood.

• Transgenic animal = animal with a foreign gene inserted into its genome
• The foreign gene is called a transgene
• Mice are the most commonly used transgenic animals (>95%)
• Transgene is typically introduced at the embryo stage (microinjection into pronucleus of fertilized egg)
• The transgene is heritable — passed to offspring

Why Make Transgenic Animals

NCERT lists five key applications: normal physiology studies, disease models, biological product production, vaccine safety testing, and chemical safety testing.

Transgenic animals aren't created for fun — each serves a serious scientific or medical purpose. NCERT lists five key applications, and NEET tests all of them.

• 1. Normal physiology & development — study how genes regulate growth, development, and biological processes (e.g., studying gene regulation in complex organisms)
• 2. Study of disease — transgenic mice models for human diseases like cancer, cystic fibrosis, Alzheimer's — helps understand disease mechanisms
• 3. Biological products — produce useful human proteins in animal milk (molecular pharming/pharming)
• 4. Vaccine safety testing — transgenic animals as models to test vaccine safety before human trials
• 5. Chemical safety testing — toxicity testing of drugs and chemicals (transgenic animals are more sensitive indicators than normal animals)

Rosie the Cow & Molecular Pharming

Rosie was the first transgenic cow that produced human alpha-lactalbumin-enriched milk. Molecular pharming uses transgenic animals to produce valuable human proteins in their milk.

Rosie (1997) was the first transgenic cow that produced human protein-enriched milk. Her milk contained human alpha-lactalbumin (2.4 g/litre) — making it more nutritionally balanced for human babies than regular cow milk. This was a proof-of-concept for molecular pharming.

• Rosie — first transgenic cow, produced human -lactalbumin in milk (2.4 g/L)
• -1-antitrypsin — produced in transgenic sheep milk, used to treat emphysema (lung disease)
• Human protein C — anticoagulant produced in transgenic animal milk
• Antithrombin III (ATryn) — first pharming product approved by FDA (from transgenic goats)
• This approach is called molecular pharming or biopharming

Gene Therapy

Gene therapy corrects a genetic defect by delivering a functional copy of the defective gene into the patient's cells. ADA deficiency was the first disease treated with gene therapy (1990), using ex vivo retroviral vector-mediated gene transfer into lymphocytes.

Gene Therapy

Gene therapy is a collection of methods that allows correction of a gene defect by inserting a normal, functional gene into cells of an individual to compensate for the defective gene.

Gene therapy is the ultimate fix — instead of treating symptoms (like giving insulin to a diabetic), you fix the root cause by replacing or supplementing the defective gene with a functional copy. The normal gene is delivered into the patient's cells using a vector (usually a modified virus).

• Gene therapy inserts a normal gene to compensate for the defective one
• It targets the cause (faulty gene), not just the symptoms
• Genes are delivered using vectors — usually modified retroviruses
• Can be ex vivo (cells removed, modified outside, put back) or in vivo (gene delivered directly into body)
• Currently limited to somatic cells (body cells) — germ line gene therapy is banned in most countries

ADA Deficiency

Adenosine deaminase (ADA) deficiency causes Severe Combined Immunodeficiency (SCID). In 1990, the first approved gene therapy trial treated a 4-year-old girl (Ashanti DeSilva) by inserting a functional ADA gene into her lymphocytes.

Adenosine deaminase (ADA) is an enzyme crucial for the immune system. Without ADA, toxic metabolites (deoxyadenosine) accumulate and destroy T-lymphocytes, leaving the child with virtually no functional immune system — this condition is called Severe Combined Immunodeficiency (SCID). These children can die from even a minor infection.

Gene Therapy for ADA Deficiency — The NCERT Protocol

1. Lymphocytes are extracted from the patient's blood
2. A functional ADA gene is cloned into a retroviral vector
3. The retroviral vector infects the lymphocytes in the lab (ex vivo)
4. The functional ADA gene integrates into the lymphocyte genome
5. Modified lymphocytes (now producing ADA) are infused back into the patient
6. Patient's immune system is restored — lymphocytes can now function
7. However, these lymphocytes are not immortal — patient needs periodic infusions

• ADA = Adenosine Deaminase — enzyme needed for immune function
• ADA deficiency arrow SCID (Severe Combined Immunodeficiency)
• First gene therapy: 1990, patient: Ashanti DeSilva (4-year-old girl)
• Method: Ex vivo — lymphocytes removed, modified with retroviral vector, returned
• The cure is NOT permanent — modified lymphocytes die, need repeated infusions
• Permanent cure would require fixing the gene in bone marrow stem cells (early embryo)

Alternative treatment for ADA deficiency: Bone marrow transplant from a matched donor or injection of PEG-ADA (enzyme replacement). But gene therapy offers the possibility of fixing the root cause.

Applications in Medicine & Agriculture

Biotechnology has transformed medicine (recombinant insulin, hGH, hepatitis B vaccine, molecular diagnostics via PCR and ELISA) and agriculture (GM crops like Flavr Savr tomato, Golden Rice). These applications form the backbone of applied biotechnology questions in NEET.

Recombinant Insulin

Before 1983, diabetics used insulin extracted from pig and cow pancreases, which caused allergies. Eli Lilly produced the first recombinant human insulin (Humulin) using E. coli — identical to natural human insulin.

Insulin was the first therapeutic protein produced using rDNA technology. Before 1983, insulin came from slaughtered pigs and cattle — animal insulin caused allergies in some patients and required massive numbers of animals. Eli Lilly (1983) solved this by producing human insulin in E. coli.

Eli Lilly's Strategy for rDNA Insulin

1. Human insulin gene was too complex to express directly in bacteria (introns, post-translational processing)
2. Eli Lilly prepared two DNA sequences corresponding to A chain and B chain separately
3. Each chain was produced separately in E. coli as fusion proteins
4. A and B chains were extracted and purified
5. Chains were combined by creating disulfide bonds in vitro
6. Result: Humulin — recombinant human insulin identical to natural insulin

• Insulin = first genetically engineered therapeutic protein
• Human insulin: A chain (21 aa) + B chain (30 aa) linked by disulfide bonds
• Proinsulin = A + B + C peptide (C peptide removed during maturation)
• Eli Lilly (1983): produced A and B chains separately in E. coli, then combined them
• Product: Humulin — identical to human insulin, no allergic reactions
• Before rDNA: insulin from animal pancreases caused allergies in some patients

hGH & Recombinant Vaccines

Human growth hormone (hGH) was earlier extracted from cadaver pituitaries (risky). Recombinant hGH and Hepatitis B vaccine (produced in yeast) are major biotechnology success stories.

Human Growth Hormone (hGH) was previously extracted from the pituitary glands of cadavers (dead bodies) — a process that was expensive, limited in supply, and risky (Creutzfeldt-Jakob disease transmission). Now, recombinant hGH is produced in bacteria — safe, unlimited supply.

• hGH — treats pituitary dwarfism in children
• Earlier source: cadaver pituitaries (risk of prion disease transmission)
• Now: produced by rDNA technology in bacteria — safe and abundant
• Hepatitis B vaccine — first recombinant vaccine approved (1986)
• Hep B vaccine: HBsAg (surface antigen) gene expressed in yeast (*Saccharomyces cerevisiae*)
• No live virus used — just the surface protein — cannot cause infection

Molecular Diagnosis

Traditional diagnosis waits for symptoms. Molecular diagnosis (PCR, ELISA, autoradiography) detects disease at the genetic or molecular level — earlier, faster, more accurate.

Conventional diagnosis relies on symptoms and serology — but by the time symptoms appear, the disease is often advanced. Molecular diagnosis detects pathogens or genetic defects at the DNA/RNA or protein level — catching disease earlier and more accurately.

• PCR (Polymerase Chain Reaction) — amplifies specific DNA sequences; detects very low pathogen levels
• ELISA (Enzyme-Linked Immunosorbent Assay) — detects specific antigens or antibodies using enzyme-linked antibodies
• Autoradiography — uses radioactive probes to detect specific DNA/RNA sequences
• PCR can detect HIV before antibodies appear in blood (unlike ELISA)
• ELISA is used for: HIV screening, pregnancy tests, food allergen detection
• These techniques detect disease before symptoms appear — critical for early treatment

GM Foods

Genetically modified (GM) foods have enhanced traits like delayed ripening, improved nutrition, or pest resistance. Flavr Savr tomato (1994) was the first commercially grown GM food crop.

Genetically Modified (GM) foods are derived from organisms whose DNA has been altered using genetic engineering. The goals include: better nutrition (Golden Rice with vitamin A), longer shelf life (Flavr Savr tomato), pest resistance (Bt crops), and herbicide tolerance (Roundup Ready soybean).

• Flavr Savr tomato (1994) — first GM food approved for sale (USA, by Calgene)
• Flavr Savr had delayed ripening — stayed fresh longer during transport
• Mechanism: antisense RNA against polygalacturonase gene arrow slowed cell wall degradation
• Golden Rice — engineered to produce -carotene (provitamin A) in the endosperm
• Golden Rice addresses vitamin A deficiency — a major problem in Asia and Africa
• GM crops: over 180 million hectares cultivated worldwide (as of recent data)

Bioethics & Biopiracy

As biotechnology advances, ethical questions arise about GMO safety, gene patenting, and exploitation of biodiversity. GEAC regulates GM research in India. Biopiracy — the patenting of traditional knowledge and biological resources by foreign entities — is a major concern, with turmeric, neem, and basmati rice being famous Indian cases.

Ethical Issues of GMOs

Genetically modified organisms raise concerns about environmental safety, human health, economic impact on farmers, and moral boundaries of 'playing God' with DNA.

The development of GM organisms (GMOs) has triggered intense debate worldwide. Three major areas of concern exist: environmental safety (will GM crops harm ecosystems?), human health (are GM foods safe to eat?), and socio-economic impact (will GM seeds make farmers dependent on corporations?).

• Environmental concerns: GM crops may transfer genes to wild relatives (gene flow), reduce biodiversity, harm non-target organisms
• Health concerns: Potential allergenicity, antibiotic resistance markers, unknown long-term effects
• Socio-economic: Terminator seeds (sterile), corporate monopoly, farmers' rights, seed costs
• Ethical: Is it morally right to transfer genes across species? (e.g., fish gene in tomato for cold resistance)
• Religious: Some groups oppose GMOs on the grounds that it's 'playing God' with creation

GEAC

The Genetic Engineering Appraisal Committee (GEAC) is the Indian regulatory body that approves or rejects proposals for GM research and commercial release of GM organisms.

In India, the Genetic Engineering Appraisal Committee (GEAC) is the apex body that makes decisions on the validity of GM research and the safety of introducing GM organisms for public use. It operates under the Ministry of Environment, Forest and Climate Change.

• Full form: Genetic Engineering Appraisal Committee (earlier called Approval Committee — renamed to Appraisal)
• Under: Ministry of Environment, Forest and Climate Change (MoEFCC)
• Function: Approves/rejects proposals for GM research, field trials, and commercial release
• Authority: Can impose conditions, monitor compliance, and order destruction of unapproved GM crops
• GEAC approved Bt cotton (2002) — India's only commercially approved GM crop

Biopiracy

Biopiracy is the unauthorized use of biological resources and traditional knowledge of developing countries by multinational corporations, often through patents. India's turmeric, neem, and basmati cases are landmark examples.

Biopiracy refers to the exploitation of biological resources and traditional knowledge of developing countries by developed-world organizations/corporations, who patent these resources without proper authorization, acknowledgment, or compensation to the source country.

• Turmeric patent (1995): US Patent Office granted patent on turmeric's wound-healing properties to University of Mississippi. India challenged it — patent revoked in 1997 (prior art from ancient texts)
• Neem patent (1994): European Patent Office granted patent on neem-based biopesticide to W.R. Grace & Co. India challenged — patent revoked in 2005 after 11-year battle
• Basmati rice (1997): US company RiceTec got patent on 'Basmati' rice lines. India challenged — several claims struck down
• India's response: Created Traditional Knowledge Digital Library (TKDL) — a database of traditional knowledge in patent-searchable format
• TKDL documents 2.5 lakh formulations from ancient Indian texts (Ayurveda, Unani, Siddha)

Biosafety & Patent Issues

The patenting of life forms and genes raises fundamental questions about ownership of biological material. International frameworks like the Cartagena Protocol address biosafety of GMOs.

Can you patent a gene? Can a company own a life form? These questions became real when the US Supreme Court allowed patenting of a genetically modified bacterium (*Pseudomonas* that could degrade oil) in 1980 (Diamond v. Chakrabarty case). Since then, thousands of gene patents have been granted worldwide.

• Cartagena Protocol on Biosafety (2000) — international agreement on safe transfer, handling, and use of GMOs across countries
• Convention on Biological Diversity (CBD) — nations have sovereign rights over their biological resources
• TRIPS Agreement (WTO) — requires member nations to provide patent protection for inventions, including biotech products
• Conflict: TRIPS promotes patents, CBD promotes sovereignty over bio-resources — developing countries caught in between
• India's Patent Act (amended 2005) — allows patenting of biotech products but has safeguards against biopiracy

• Gene patents — controversial because genes are discoveries (natural), not inventions (man-made)
• Farmer's rights — should farmers pay royalties every season for patented GM seeds?
• Terminator technology — GM seeds that produce sterile plants, forcing farmers to buy new seeds each year (widely condemned)
• Bioethics committees worldwide monitor and regulate the ethical boundaries of biotechnology